An immunosuppressive tumor microenvironment is a major challenge for existing immunotherapies. A novel form of immunotherapy, known as peptide alarm therapy, has shown promise in activating the immune system within tumors by injecting viral peptides.
The newly approved Lifileucel stimulates tumor-infiltrating lymphocytes (TILs) unspecifically. Researchers are now investigating the degree to which neoantigens contribute to tumor regression under TIL therapy.